

INTRODUCING

Nobivac[®] NXT
© **Canine Flu H3N2**



*DELIVER
NXT-LEVEL
IMMUNITY*

Fight canine influenza virus (CIV) with revolutionary RNA particle technology in a non-adjuvanted, low-volume vaccine



A novel solution to a prevailing threat

Introducing the next (NXT) generation of protection from Merck Animal Health's line of Nobivac® respiratory vaccines. Nobivac® NXT Canine Flu H3N2 is a groundbreaking new way to safeguard dogs against the ongoing threat of canine flu.

See how Nobivac® continues its legacy of innovation with NXT-level immunity.

Leading canine respiratory protection for 15 years

2009

First canine flu (H3N8) vaccine with Nobivac® Canine Flu H3N8

2016

First bivalent canine flu vaccine for both H3N2 and H3N8 with Nobivac® Canine Flu Bivalent

2018

The first and only flu vaccine approved for both canine and feline use with Nobivac® Canine Flu H3N2

NOW

Nobivac® NXT
Canine Flu H3N2

THE NOBIVAC® NXT ADVANTAGE



First and only canine flu vaccine built on RNA particle technology



RNA particles stimulate the immune system to attack the H3N2 virus without the use of adjuvants or live organisms



A low-volume 0.5-mL dose provides a more gentle vaccine experience

Laboratory surveillance indicates CIV H3N2 as the critical strain of concern.¹



Groundbreaking technology. Exceptional protection.



The first and only line of companion animal vaccines to use RNA particle technology to generate an efficient, comprehensive immune response.

- ✓ **Smaller dose**
A low-volume 0.5-mL dose for a more gentle vaccine experience
- ✓ **No extraneous material**
NXT-level protection in a preservative-free, adjuvant-free, thimerosal-free formulation
- ✓ **Targeted and efficient**
Delivers the desired viral sequence to dendritic cells for an enhanced, precise immune response
- ✓ **Safety and efficacy without compromise**
Self-amplification triggers a robust antibody and cellular immune response without the use of an adjuvant or live organisms


See how this NXT-level technology works



Nobivac[®] NXT
© Canine Flu H3N2


The NXT generation of vaccine technology

A closer look at comprehensive immune activation



How Nobivac[®] NXT triggers a comprehensive immune response

Nobivac[®] NXT vaccines deliver RNA particles to harness the natural ability of the immune system to generate a robust response with no compromise to comfort or safety.




Uncompromising efficacy

A challenge study involving 8-week-old puppies showed that Nobivac® NXT Canine Flu H3N2 significantly reduces coughing and lung lesion scores* ($P < 0.0001$).


Robust protection



Median Duration of Coughing^{1†}




Median Lung Lesion Score^{1†}



Highly effective in protecting the lungs

Duration of viral shedding significantly reduced[#]



Decreased shedding reduces the opportunity for CIV to infect other dogs.

Demonstrated safety under field conditions

Proven safe across a variety of breeds and ages in a field safety study¹

- ✓ 1,301 doses administered to 654 dogs of various breeds
- ✓ Dogs ranged in age from 8 weeks to 15 years
- ✓ Lethargy was the most common adverse event (1.6%)

* The standardized method of evaluating efficacy of canine influenza vaccines is based on lung lobe consolidation.²
¹ Two doses of Nobivac® NXT Canine Flu H3N2 at field dose were administered subcutaneously, 3 weeks apart. Clinical observations were recorded for 10 days post-challenge, and nasal swabs were collected for 10 consecutive days to determine viral shedding. Lungs were evaluated 10 days following challenge.
[†] $P < 0.0001$

Nobivac® NXT
Canine Flu H3N2

Nobivac® NXT Canine Flu H3N2

The NXT chapter in respiratory protection

- ✓ The latest innovation from a leader in respiratory protection
- ✓ NXT-generation protection against canine influenza virus H3N2
- ✓ Enhances the body's natural processes to induce comprehensive immunity
- ✓ A low-volume 0.5-mL dose provides a more gentle vaccine experience
- ✓ The ONLY adjuvant-free canine influenza vaccine
- ✓ Optimized safety and efficacy for total peace of mind



Talk to your Merck Animal Health
representative to learn more.

Technical Services: 1-800-224-5318
(Monday-Friday, 9:00 AM-7:00 PM ET)

Customer Service: 1-800-521-5767
(Monday-Friday, 9:00 AM-6:00 PM ET)

References: 1. Data on file. Merck Animal Health. 2. Deshpande MS, Jirjis FF, Tubbs AL, et al. Evaluation of the efficacy of a canine influenza virus (H3H8) vaccine in dogs following experimental challenge. *Vet Therapeut.* 2009;10(3):103-112.

All trademarks are property of their respective owners.

Copyright © 2024 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved. US-NOV-240400002 897450

